臺灣博碩士論文加值系統

背景介紹
結核病以及癌症乃是兩個全球相當重要之傳染性以及非傳染性疾病，在公衛的領域中，針對這兩個疾病的預防醫學，是相當重要的課題，因此，我們針對這兩個全球性的重要疾病，在初級，次級以及三級預防中，探討關鍵的課題以及研究。
方法與程序
在初級預防中，我們探討糖尿病是否會增加潛伏結核感染的風險，在過去的研究中，主要是發現糖尿病會增加活動性結核的風險以及影響預後，對於潛伏結核感染這一塊，少有著墨，而我們將利用統合分析的方式，來研究糖尿病是否會增加結核潛伏感染的風險。
在次級預防中，我們探討一個新的氟喹諾酮(fluoroquinolone)，gemifloxacin，是否會造成結核診斷延誤，過去認為針對結核病患者使用對於結核菌有效之氟喹諾酮類抗生素，會造成結核病患者症狀改善，而造成診斷延誤，而新一代的氟喹諾酮gemifloxacin，因為其對於結核菌無抗菌力，是否就因此而比較不會造成結核病診斷延誤，則尚未有定論。在這研究中，我們將使用北台灣多中心三家醫院的患者資料以及臺灣的健保資料庫，進行世代研究。
在三級預防中，我們分析，是否入住加護病房，對於發生敗血性休克的第四期癌症患者的長期預後是否有幫助。過去認為，因為第四期癌症患者普遍預後極差，因此當產生重症疾患如敗血性休克時，入住加護病房接受積極治療，將只是帶來患者痛苦而對於整體預後幫助不大，但是隨著癌症以及重症醫療的進步，此一觀念是否需要改變則尚屬未知，本研究則將利用臺灣癌症登記檔以及臺灣健保資料庫進行串聯分析。
結果
在初級預防議題中，我們統合了十三個研究，收入了七個國家，38263受試者，發現糖尿病跟潛伏結核感染有統計上顯著的相關性，但是其強度並沒有一般認為的高(OR:1.18(95% CI:1.06-1.30))。
在次級預防議題中，藉由收入了醫院世代201位患者以及健保資料庫世代中3544位患者，我們發現在經由傾向分數(propensity score)配對後，使用gemifloxacin的患者並沒有較短的結核病診斷延誤。
在三級預防中，我們共收入了11825位第四期癌症併敗血性休克的患者，其中有6089位患者有入住加護病房，整體院內死亡率約七成，經由傾向分數配對後，我們發現入住加護病房的患者有較佳的整體存活HR: 0.76, 95% CI: 0.72-0.79)，較低的院內死亡率(OR: 0.61, 95% CI: 0.55-0.68)，以及較佳的出院後存活(HR: 0.77, 95% CI: 0.70-0.85)。
討論與結論
根基於我們的研究，我們確立了糖尿病會增加潛伏結核感染的風險，但由於風險比並不如想像的高，要特地針對糖尿病進行潛伏結核感染篩檢仍需有更全盤的考慮。而對於結核病的診斷的部分，高的臨床警覺性加上積極進行相關結核菌學檢查依然是縮短診斷延誤的關鍵，而在診斷前使用不同的抗生素可能差距不如想像中的大。最後，雖然入住加護病房可以增加第四期癌症患者併敗血性休克患者的存活率，但是院內死亡率依然很高，因此完整的醫病溝通，依然是下相關醫療決策不可或缺的一環。

Introduction
Tuberculosis (TB) and cancer are two major global communicable and non-communicable diseases. In the field of public health, preventive medicine regarding these two diseases are important issues. We, therefore, targeted primary, secondary and tertiary prevention of these two important global diseases.
Materials and Methods
In primary prevention, we discussed whether diabetes mellitus (DM) was associated with higher risk of latent tuberculosis infection. In past studies, DM was found to increase risk of active TB and had impact on clinical outcome. The association between diabetes and latent tuberculosis infection (LTBI), however, was scant in studies. We used meta-analysis to discuss if diabetes was associated with risk of latent tuberculosis infection.
In secondary prevention, we discussed whether a newer fluoroquinolone (FQ), gemifloxacin, will lead to TB treatment delay. In the past, using FQs with effects on TB prior to TB diagnosis will lead to clinical improvement and cause treatment delay. Newer FQ, gemifloxacin, has little anti-TB effect and some have proposed that use of gemifloxacin prior to TB diagnosis would reduce TB treatment delay compared with other FQs. In this study, we recruited two cohorts from three hospitals in northern Taiwan and also from Taiwan national health insurance claims (NHI) database.
In tertiary prevention, we analyzed whether admission to intensive care unit (ICU) is beneficial to stage IV septic shock patients long-term survial. In past studies, a pessimistic attitude was held toward admitting late-stage cancer patients to ICU for septic shock management. Admission to ICU was considered futile, lead to patients suffering and did not bring much benefit to patients. As cancer and critical care treatment improved, current concepts have also gradually changed. In this study, we used linkage between Taiwan cancer registry and Taiwan NHI database for patients recruitment.
Results
In primary prevention, we included 13 studies with 38263 participants from 7 nations. We found that there was an association between diabetes mellitus and LTBI (OR:1.18(95% CI:1.06-1.30)). The association appeared to be lower than previously perceived.
In secondary prevention, we included 201 patients in the hospital-based cohort and 3544 patients in the population-based cohort. After propensity score matching, we found that there was no evidence that use of gemifloxacin leads to shorter TB treatment delay.
In tertiary prevention, we included 11825 stage IV cancer patients with septic shock. Among them, 6089 patients were admitted to ICU with an overall 70% in-hospital mortality rate. After PS matching, we found that admission to ICU was associated with better overall survival(HR: 0.76, 95% CI: 0.72-0.79), lower in-hospital mortality rate (OR: 0.61, 95% CI: 0.55-0.68) and better post-discharge long-term survival (HR: 0.77, 95% CI: 0.70-0.85).
Discussion and conclusions
Based on our study, we found that diabetes mellitus was associated with higher risk of LTBI. The risk, however, was not higher than expected and targeting DM patients for LTBI screening may need more consideration. For TB diagnosis, high clinical alertness and aggressive TB survey remain the key to reducing TB treatment delay. Using different antibiotics prior to TB diagnosis may make little difference. Last, though admission to ICU could improve stage IV cancer patients with septic shock survival rate, the in-hospital mortality remains high. Thorough and detailed communication between phyisicians, patients and families remained irreplaceable.

口試委員會審定書 2
誌謝 3
中文摘要 4-5
英文摘要 6-8
第一章 簡介與文獻回顧 9-14
第二章 研究方法 15-25
第三章 結果 26-35
第四章 討論 36-50
第五章 結論 51
參考文獻 52-61
附錄 62-114
 

1.Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology 2016 Dec 03.
2.Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016 Oct 08;388(10053):1545-602.
3.Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA oncology 2015 Jul;1(4):505-27.
4.Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet Infectious diseases 2016 Apr;16(4):e34-46.
5.Organization WH. Global Tuberculosis Report 2015. 20th Edn. Geneva: World Health Organization, 2015.
6.Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014 Sep 13;384(9947):1005-70.
7.Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract 2014 Nov;106(2):191-9.
8.Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015 Dec;46(6):1563-76.
9.Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014 Mar;44(3):617-26.
10.Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016 Apr 9;387(10027):1513-30.
11.Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS medicine 2008 Jul 15;5(7):e152.
12.Alvarez GG, VanDyk DD, Aaron SD, et al. Taima (stop) TB: the impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit, Nunavut. PloS one 2014;9(7):e100975.
13.Lee SS, Chou KJ, Dou HY, et al. High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test. Clinical journal of the American Society of Nephrology : CJASN 2010 Aug;5(8):1451-7.
14.Hensel RL, Kempker RR, Tapia J, Oladele A, Blumberg HM, Magee MJ. Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus. Int J Tuberc Lung Dis 2016 Jan;20(1):71-8.
15.Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA 2016 Feb 9;315(6):593-602.
16.Gillespie SH. The role of moxifloxacin in tuberculosis therapy. European respiratory review : an official journal of the European Respiratory Society 2016 Mar;25(139):19-28.
17.Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002 Jun 15;34(12):1607-12.
18.Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006 Oct;61(10):903-8.
19.Wang JY, Lee CH, Yu MC, Lee MC, Lee LN, Wang JT. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. Eur Respir J 2015 Aug;46(2):567-70.
20.Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacother 2004 Jul-Aug;38(7-8):1226-35.
21.Tan CK, Lai CC, Liao CH, et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2009 Aug;64(2):428-9.
22.Kim SY, Yim JJ, Park JS, et al. Clinical effects of gemifloxacin on the delay of tuberculosis treatment. J Korean Med Sci 2013 Mar;28(3):378-82.
23.Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016 Oct 08;388(10053):1459-544.
24.Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010 Aug 19;363(8):733-42.
25.Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Current oncology reports 2016 Feb;18(2):9.
26.Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet 2016 Nov 26;388(10060):2654-64.
27.Cameron JI, Chu LM, Matte A, et al. One-Year Outcomes in Caregivers of Critically Ill Patients. N Engl J Med 2016 May 12;374(19):1831-41.
28.Jutte JE, Erb CT, Jackson JC. Physical, Cognitive, and Psychological Disability Following Critical Illness: What Is the Risk? Semin Respir Crit Care Med 2015 Dec;36(6):943-58.
29.Wright AA, Keating NL, Ayanian JZ, et al. Family Perspectives on Aggressive Cancer Care Near the End of Life. JAMA 2016 Jan 19;315(3):284-92.
30.Garrouste-Orgeas M, Montuclard L, Timsit JF, et al. Predictors of intensive care unit refusal in French intensive care units: a multiple-center study. Crit Care Med 2005 Apr;33(4):750-5.
31.Yun YH, Lee MK, Kim SY, et al. Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. J Clin Oncol 2011 Jun 20;29(18):2474-80.
32.Staudinger T, Stoiser B, Mullner M, et al. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 2000 May;28(5):1322-8.
33.Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth 2012 Mar;108(3):452-9.
34.Ostermann M, Ferrando-Vivas P, Gore C, Power S, Harrison D. Characteristics and Outcome of Cancer Patients Admitted to the ICU in England, Wales, and Northern Ireland and National Trends Between 1997 and 2013. Crit Care Med 2017 Jul 04.
35.Groeger JS, Bach PB. Consider saying yes. Crit Care Med 2003 Jan;31(1):320-1.
36.Raoof ND, Groeger JS. You never know--one of your patients with cancer might surprise you. Crit Care Med 2007 Mar;35(3):965-6.
37.Xia R, Wang D. Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study. BMC cancer 2016 Mar 05;16:188.
38.Wallace SK, Rathi NK, Waller DK, et al. Two Decades of ICU Utilization and Hospital Outcomes in a Comprehensive Cancer Center. Crit Care Med 2016 May;44(5):926-33.
39.Soares M, Darmon M, Ferreira CG, et al. Outcomes of critically ill patients with lung cancer. J Clin Oncol 2006 Jun 20;24(18_suppl):16001.
40.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009 Aug 18;151(4):264-9, W64.
41.Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008 Aug 05;149(3):177-84.
42.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010 Sep;25(9):603-5.
43.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 06;327(7414):557-60.
44.Patra J, Bhatia M, Suraweera W, et al. Exposure to second-hand smoke and the risk of tuberculosis in children and adults: a systematic review and meta-analysis of 18 observational studies. PLoS medicine 2015 Jun;12(6):e1001835; discussion e.
45.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 Jun 15;21(11):1539-58.
46.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 Sep 13;315(7109):629-34.
47.Chen CC, Chiang CY, Pan SC, Wang JY, Lin HH. Health system delay among patients with tuberculosis in Taiwan: 2003-2010. BMC infectious diseases 2015 Nov 02;15:491.
48.Lai CC, Lee MT, Lee SH, et al. Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort. Thorax 2016 Jul;71(7):646-51.
49.Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest 2015 Feb;147(2):520-8.
50.Lee CH, Lee MC, Lin HH, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PloS one 2012;7(5):e37978.
51.Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 2009 Nov;31(11):2665-77.
52.Lai CL, Wu CF, Kuo RN, et al. Clinical outcomes in low risk coronary artery disease patients treated with different limus-based drug-eluting stents--a nationwide retrospective cohort study using insurance claims database. PloS one 2015;10(4):e0122860.
53.Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol 2015 Mar;45(3):291-6.
54.Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 Jul;29(7):1303-10.
55.Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 Jun;45(6):613-9.
56.Hsu CC, Lee CH, Wahlqvist ML, et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes Care 2012 Nov;35(11):2286-92.
57.Chia-Tien Chang S-CW, Yen-Ni Hung, Yee-Yung Ng, Hui-Shan Chen. The effects of individual and neighborhood socioeconomic status on early nephrology referral for hemodialysis patients. Taiwan Journal of Public Health 2014;02:75-88.
58.Lai CL, Chen HM, Liao MT, Lin TT, Chan KA. Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. Journal of the American Heart Association 2017 Apr 24;6(4).
59.Arnedo-Pena A, Juan-Cerdan JV, Romeu-Garcia MA, et al. Vitamin D status and incidence of tuberculosis infection conversion in contacts of pulmonary tuberculosis patients: a prospective cohort study. Epidemiol Infect 2015 Jun;143(8):1731-41.
60.Suwanpimolkul G, Grinsdale JA, Jarlsberg LG, et al. Association between diabetes mellitus and tuberculosis in United States-born and foreign-born populations in San Francisco. PloS one 2014;9(12):e114442.
61.Organization WH. Collaborative framework for care and control of tuberculosis and diabetes 2011.
62.Shu CC, Wu VC, Yang FJ, et al. Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PloS one 2012;7(8):e42592.
63.Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009 Jul;20(4):488-95.
64.Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014 Feb;103(2):150-60.
65.Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007 Nov;30(5):945-50.
66.Faurholt-Jepsen D, Aabye MG, Jensen AV, et al. Diabetes is associated with lower tuberculosis antigen-specific interferon gamma release in Tanzanian tuberculosis patients and non-tuberculosis controls. Scand J Infect Dis 2014 May;46(5):384-91.
67.Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015 May 28;372(22):2127-35.
68.Repasy T, Lee J, Marino S, et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis in vivo. PLoS pathogens 2013 Feb;9(2):e1003190.
69.Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI. Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control. Tuberculosis (Edinb) 2013 Mar;93(2):192-7.
70.Vallerskog T, Martens GW, Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J Immunol 2010 Jun 1;184(11):6275-82.
71.Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis (Edinb) 2013 Dec;93 Suppl:S10-4.
72.Pan SC, Chen CC, Chiang YT, Chang HY, Fang CT, Lin HH. Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study. Am J Public Health 2016 Jul;106(7):1323-8.
73.Ting WY, Huang SF, Lee MC, et al. Gender disparities in latent tuberculosis infection in high-risk individuals: a cross-sectional study. PloS one 2014;9(11):e110104.
74.Khawcharoenporn T, Apisarnthanarak A, Phetsuksiri B, Rudeeaneksin J, Srisungngam S, Mundy LM. Tuberculin skin test and QuantiFERON-TB Gold In-tube Test for latent tuberculosis in Thai HIV-infected adults. Respirology 2015 Feb;20(2):340-7.
75.Cudahy P, Shenoi SV. Diagnostics for pulmonary tuberculosis. Postgrad Med J 2016 Apr;92(1086):187-93.
76.Lee MR, Chung KP, Wang HC, et al. Evaluation of the Cobas TaqMan MTB real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Med Microbiol 2013 Aug;62(Pt 8):1160-4.
77.Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane database of systematic reviews 2014 Jan 21(1):CD009593.
78.Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. The Lancet Infectious diseases 2018 Jan;18(1):76-84.
79.Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015 Apr 2;372(14):1312-23.
80.Tseng YT, Chuang YC, Shu CC, Hung CC, Hsu CF, Wang JY. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care 2012 Oct 25;16(5):R207.
81.Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdisciplinary perspectives on infectious diseases 2012;2012:976273.
82.Cheng S, Chen W, Yang Y, et al. Effect of Diagnostic and Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An Observational Cohort Study, 1993-2010. PloS one 2013;8(6):e67516.
83.Wang M, Fitzgerald JM, Richardson K, et al. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic? Int J Tuberc Lung Dis 2011 Aug;15(8):1062-8.
84.Lee JY, Lee HJ, Kim YK, et al. Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients. Antimicrob Agents Chemother 2016 Jul;60(7):4005-12.
85.Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011 Mar;15(3):e211-6.
86.Seifert M, Georghiou SB, Garfein RS, Catanzaro D, Rodwell TC. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clin Infect Dis 2017 Sep 1;65(5):772-8.
87.Jorstad MD, Amus J, Marijani M, Sviland L, Mustafa T. Diagnostic delay in extrapulmonary tuberculosis and impact on patient morbidity: A study from Zanzibar. PloS one 2018;13(9):e0203593.
88.Orlando S, Triulzi I, Ciccacci F, et al. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF. PloS one 2018;13(7):e0200523.
89.Lee CH, Wang JY, Lin HC, et al. Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study. BMC infectious diseases 2017 Jun 24;17(1):449.
90.Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1;44 Suppl 2:S27-72.
91.Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004 Aug;98(8):708-20.
92.Ruiz-Serrano MJ, Alcala L, Martinez L, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000 Sep;44(9):2567-8.
93.Liu Y, Zhang Y, Wu J, et al. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2017 Dec;50(6):811-20.
94.Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007 May;59(5):860-5.
95.Pene F, Percheron S, Lemiale V, et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 2008 Mar;36(3):690-6.
96.Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012 Jan;40(1):43-9.
97.Shrime MG, Ferket BS, Scott DJ, et al. Time-Limited Trials of Intensive Care for Critically Ill Patients With Cancer: How Long Is Long Enough? JAMA oncology 2016 Jan;2(1):76-83.
98.Zampieri FG, Mazza B. Mechanical Ventilation in Sepsis: A Reappraisal. Shock 2017 Jan;47(1S Suppl 1):41-6.
99.Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017 Mar;43(3):304-77.
100.Coba V, Whitmill M, Mooney R, et al. Resuscitation bundle compliance in severe sepsis and septic shock: improves survival, is better late than never. J Intensive Care Med 2011 Sep-Oct;26(5):304-13.
101.Koyner JL, Murray PT. Mechanical ventilation and lung-kidney interactions. Clinical journal of the American Society of Nephrology : CJASN 2008 Mar;3(2):562-70.
102.Esteban A, Frutos-Vivar F, Ferguson ND, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 2007 May;35(5):1284-9.
103.Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996 Jul;22(7):707-10.
104.Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008 Feb 19;148(4):258-67.
105.Cheng KC, Lu CL, Chung YC, et al. ICU service in Taiwan. Journal of intensive care 2014;2(1):8.
106.Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014 Apr 2;311(13):1308-16.
107.Labelle A, Juang P, Reichley R, et al. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Crit Care Med 2012 Jul;40(7):2016-21.
108.Halpern NA, Pastores SM, Oropello JM, Kvetan V. Critical care medicine in the United States: addressing the intensivist shortage and image of the specialty. Crit Care Med 2013 Dec;41(12):2754-61.
109.Truog RD, Brock DW, Cook DJ, et al. Rationing in the intensive care unit. Crit Care Med 2006 Apr;34(4):958-63; quiz 71.
110.VanderWalde NA, Salloum RG, Liu TL, et al. Positron emission tomography and stage migration in head and neck cancer. JAMA otolaryngology-- head & neck surgery 2014 Jul;140(7):654-61.
111.Hodgson CL, Udy AA, Bailey M, et al. The impact of disability in survivors of critical illness. Intensive Care Med 2017 May 22.
112.Hsiao WC, Cheng SH, Yip W. What can be achieved with a single-payer NHI system: The case of Taiwan. Soc Sci Med 2016 Dec 7.
113.Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell TC. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health 2014 Apr;104(4):e95-e102.
114.Chan-Yeung M, Cheung AH, Dai DL, et al. Prevalence and determinants of positive tuberculin reactions of residents in old age homes in Hong Kong. Int J Tuberc Lung Dis 2006 Aug;10(8):892-8.
115.Jackson C, Southern J, Whitworth HS, et al. Diabetes and Latent Tuberculosis Infection: Nested Case-Control Study within the Predict Cohort. Thorax 2013 Dec;68:A31-A2.
116.Wang JY, Shu CC, Lee CH, Yu CJ, Lee LN, Yang PC. Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis. J Infect 2012 Mar;64(3):291-8.